Compare
Akari Therapeutics Plc vs Atossa Therapeutics, Inc. vs Vistagen Therapeutics, Inc. vs Verrica Pharmaceuticals Inc.
| Latest fiscal year | Akari Therapeutics Plc AKTX | Atossa Therapeutics, Inc. ATOS | Vistagen Therapeutics, Inc. VTGN | Verrica Pharmaceuticals Inc. VRCA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-03-31 | 2025-12-31 |
| Revenue | n/a | n/a | $1.27M | $35.58M |
| Revenue growth (YoY) | n/a | n/a | +161.1% | +370.2% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/m | -34.2% |
| Net margin | n/a | n/a | n/m | -50.3% |
| Net income | -$17.30M | -$34.77M | -$69.69M | -$17.89M |
| EPS (Diluted) | $0.00 | -$4.04 | -$1.83 | -$1.68 |
| Operating cash flow | -$10.57M | -$29.76M | -$66.44M | -$17.63M |
| Free cash flow | n/a | -$29.79M | n/a | -$17.63M |
| Cash & equivalents | $0 | $41.30M | $30.79M | $30.15M |
| Total assets | $47.89M | $47.61M | $48.56M | $47.13M |
| Total liabilities | $19.56M | $8.26M | $13.04M | $22.39M |
| Shareholders' equity | $28.33M | $39.35M | $35.52M | $24.74M |
| Return on year-end equity | -61.1% | -88.4% | -196.2% | -72.3% |
| Shares outstanding | 90.54B | 8.61M | n/a | 17.18M |
Revenue, most recent five fiscal years
| Fiscal year | Akari Therapeutics Plc | Atossa Therapeutics, Inc. | Vistagen Therapeutics, Inc. | Verrica Pharmaceuticals Inc. |
|---|---|---|---|---|
| Latest | n/a | $1.8K Ended 2015-12-31 | $1.27M Ended 2026-03-31 | $35.58M Ended 2025-12-31 |
| 1 year earlier | n/a | $40.1K Ended 2014-12-31 | $486.0K Ended 2025-03-31 | $7.57M Ended 2024-12-31 |
| 2 years earlier | n/a | $632.6K Ended 2013-12-31 | $1.06M Ended 2024-03-31 | $5.12M Ended 2023-12-31 |
| 3 years earlier | n/a | $481.8K Ended 2012-12-31 | n/a | $9.03M Ended 2022-12-31 |
| 4 years earlier | n/a | $1.5K Ended 2011-12-31 | $1.11M Ended 2022-03-31 | $12.00M Ended 2021-12-31 |